Welcome, Guest. Please login or register.
July 20, 2024, 05:52:23 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 263
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 58
Total: 58


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Experimental NASH Drug Reduces Liver Fat  (Read 17336 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Experimental NASH Drug Reduces Liver Fat
« on: November 30, 2017, 10:27:40 am »
GS-0976, an acetyl-CoA carboxylase inhibitor, reduced liver fat accumulation and led to small improvements in fibrosis markers in people with non-alcoholic steatohepatitis (NASH), according to a report presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting, held last week in Washington, DC.

Nearly half of study participants who took the highest dose of GS-0976 saw at least a 30 percent reduction in liver steatosis (fat accumulation), according to magnetic resonance imaging (MRI). However, a rise in triglycerides could be a concern, requiring longer-term follow-up.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.